GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Net Issuance of Preferred Stock

FluoroPharma Medical (FluoroPharma Medical) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2016)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

FluoroPharma Medical's net issuance of preferred for the three months ended in Dec. 2016 was $0.00 Mil. The number is 0, which means that FluoroPharma Medical has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

FluoroPharma Medical's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2016 was $0.00 Mil.


FluoroPharma Medical Net Issuance of Preferred Stock Historical Data

The historical data trend for FluoroPharma Medical's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Net Issuance of Preferred Stock Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.52 - - -

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FluoroPharma Medical Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FluoroPharma Medical Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus